Nanoform Finland Oyj (HEL:NANOFH)
0.7080
-0.0520 (-6.84%)
Nov 20, 2026, 6:25 PM EET
Nanoform Finland Oyj Revenue
Nanoform Finland Oyj had revenue of 840.00K EUR in the quarter ending September 30, 2026, a decrease of -10.83%. This brings the company's total for the last twelve months to 5.08M, up 17.61% year-over-year. In the year 2025, Nanoform Finland Oyj had annual revenue of 5.02M with 37.10% growth. That makes Nanoform Finland Oyj the 39,351st largest company in the world by revenue and 168th in Finland.
Revenue (ttm)
5.08M
Revenue Growth
+17.61%
P/S Ratio
10.85
Revenue / Employee
51.75K
Employees
108
Market Cap
60.65M
Revenue by Geography
- Europe 2.00M 56.4%
- United States 1.07M 30.2%
- Other 475.00K 13.4%
Fiscal year ended Dec 31, 2025 See the full Nanoform Finland Oyj breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.02M | 1.36M | 37.10% |
| Dec 31, 2024 | 3.66M | 1.10M | 42.75% |
| Dec 31, 2023 | 2.57M | -921.38K | -26.42% |
| Dec 31, 2022 | 3.49M | 1.53M | 78.42% |
| Dec 31, 2021 | 1.95M | 1.24M | 173.88% |
| Dec 31, 2020 | 713.68K | 433.68K | 154.89% |
| Dec 31, 2019 | 280.00K | -9.65K | -3.33% |
| Dec 31, 2018 | 289.65K | 44.05K | 17.93% |
| Dec 31, 2017 | 245.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Orion Oyj | 2.18B |
| Terveystalo Oyj | 1.19B |
| Pihlajalinna Oyj | 541.83M |
| Revenio Group Oyj | 157.35M |
| Optomed Oyj | 16.87M |
| Biohit Oyj | 16.13M |
| Nexstim | 11.69M |
| Modulight Oyj | 10.00M |
Nanoform Finland Oyj News
- 3 days ago - Nanoform Finland Oyj Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Nanoform Finland Oyj Quarterly report: Q3 2026 - Filings
- 3 days ago - Nanoform Finland Oyj Slides: Q3 2026 - Filings
- 3 months ago - Nanoform Finland Oyj Earnings Call Transcript: Q2 2026 - Transcripts
- 3 months ago - Nanoform Finland Oyj Quarterly report: Q2 2026 - Filings
- 3 months ago - Nanoform Finland Oyj Slides: Q2 2026 - Filings
- 3 months ago - Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated - Finanz Nachrichten
- 3 months ago - Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide - Finanz Nachrichten